A randomized, double-blind, placebo-controlled, 8-week study to evaluate the efficacy and safety of once daily atorvastatin (10 mg) in patients with elevated LDL-cholesterol

Japanese Heart Journal

Volumn 42, Issue 6, 2001, Pages 725-738

  Wang, Kuo Yang ^a   Ting, Chih Tai ^b  

^a TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Cholesterol; High density lipoprotein; Low density lipoprotein; Triglycerides

Indexed keywords

ATORVASTATIN; CHOLESTEROL; CREATINE KINASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TRIACYLGLYCEROL;

AGED; ARTICLE; ASIAN; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; DIET THERAPY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTENSION; INCIDENCE; INSOMNIA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MYALGIA; PATIENT CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINITIS; VERTIGO;

AGED; ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEIN B-100; APOLIPOPROTEINS B; CHOLESTEROL; CHOLESTEROL, LDL; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEPTANOIC ACIDS; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; PYRROLES; TRIGLYCERIDES;

EID: 0035722902     PISSN: 00214868     EISSN: None     Source Type: Journal    
DOI: 10.1536/jhj.42.725     Document Type: Article

References (28)

1. Cholesterol in the prediction of atherosclerotic disease
2. The Lipid Research Clinics Coronary Primary Prevention Trial results, I: reduction in incidence of coronary heart disease, II: The relationship of reduction in incidence of coronary heart disease to cholesterol lowering
3. Lowering blood cholesterol to prevent heart disease
4. Findings related to a priori hypotheses of the trial
5. Cholesterol reduction in cardiovascular disease: Clinical benefits and possible mechanisms
6. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
7. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
8. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol and Recurrent Events Trial investigators
9. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
10. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS)
11. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS Air Force/Texas Coronary Atherosclerosis Prevention Study
12. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES Study)
13. Safety of low-density lipoprotein cholesterol reduction with atorvastatin versus simvastatin in coronary heart disease population
14. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia
15. Comparison of statins in hypertriglyceridemia
16. Statins: Effective antiatherosclerotic therapy
17. Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia
18. A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia
19. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts
20. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators
21. Effect of atorvastatin on blood lipid levels in the first 2 weeks of treatment: A randomized, placebo-controlled study
22. Plasma triglyceride is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol: A meta-analysis of population-based prospective studies
23. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men
24. Consensus statement: Role of therapy with "statins" in patients with hypertriglyceridemia
25. Epidemiology of coronary artery disease in the Chinese
26. Serum total cholesterol and long-term coronary heart disease mortality in different cultures: Twenty-five year follow-up of the seven countries study
27. The Stul polymorphism on exon 8 of the low density lipoprotein (LDL) receptor gene: Prevalence and impact on serum lipid levels in an Asian cohort
28. Influence of two apo A4 polymorphisms at codons 347 and 360 on non-fasting plasma lipoprotein-lipids and apolipoproteins in Asian Indians